Table 3.
The incidence of adverse events, serious adverse events and withdrawal due to adverse events
| Outcome | No.of SRs | No.of original studies | No.of cases/controls | Follow-up range (weeks) | Estimate (95%CI) | P-value | 95%PI | I2(P*) | Egger’s P value |
|---|---|---|---|---|---|---|---|---|---|
| Adverse events | |||||||||
| aliskiren 75 mg vs placebo | 1 | 5 | 742/740 | 8–13 | 0.96 [0.84–1.08] | 0.48 | [0.78–1.17] | 0% (0.56) | 0.853 |
| aliskiren150mg vs placebo | 1 | 10 | 1785/1639 | 8–26 | 0.99 [0.90–1.08] | 0.77 | [0.89–1.10] | 0% (0.65) | 0.43 |
| aliskiren300mg vs placebo | 1 | 9 | 1461/1478 | 8–26 | 1.02[0.93–1.12] | 0.68 | [0.91–1.15] | 0% (0.47) | 0.876 |
| aliskiren600mg vs placebo | 1 | 3 | 499/494 | 8 | 1.24 [1.07–1.43] | 0.004 | [0.49–3.13] | 0% (0.88) | 0.083 |
| aliskiren vs ARBs | 1 | NR | NR | 4–8 | 0.98 [0.89–1.08] | 0.68 | NR | NR | NR |
| aliskiren vs lorsartan | 1 | NR | NR | 4–8 | 1.03 [0.79–1.35] | 0.83 | NR | NR | NR |
| aliskiren vs valsartan | 1 | NR | NR | 8 | 0.92[0.81–1.05] | 0.2 | NR | NR | NR |
| aliskiren vs irbesartan | 1 | NR | NR | 7–8 | 1[0.81–1.23] | 0.99 | NR | NR | NR |
| aliskiren vs ACEIs | 1 | 2 | 514/508 | 8–26 | 1[0.89–1.11] | 0.93 | NA | 0% | NA |
| aliskiren vs Amlodipine | 1 | 2 | 513/492 | 8–32 | 0.99 [0.81–1.11] | 0.92 | NA | 37% | NA |
| aliskiren vs HCTZ | 1 | 1 | 183/176 | 8 | 0.95 [0.74–1.22] | 0.68 | NA | NA | NA |
| aliskiren vs atenolol | 1 | 1 | 231/231 | 12 | 0.88 [0.72–1.08] | 0.23 | NA | NA | NA |
| Serious adverse events | |||||||||
| aliskiren vs placebo | 1 | 8 | 3633/1683 | 8–26 | 0.75 [0.27–2.05] | 0.57 | [0.07–7.71] | 32%(0.17) | 0.811 |
| aliskiren vs ARBS | 1 | NR | NR | 4–8 | 0.72 [0.36–1.46] | 0.36 | NR | NR | NR |
| aliskiren vs lorsartan | 1 | NR | NR | 4–8 | 0.33 [0.01–8.18] | 0.5 | NR | NR | NR |
| aliskiren vs valsartan | 1 | NR | NR | 8 | 0.63 [0.09–4.43] | 0.65 | NR | NR | NR |
| aliskiren vs irbesartan | 1 | NR | NR | 7–8 | 0.55[0.18–1.67] | 0.29 | NR | NR | NR |
| Withdrawal due to adverse events | |||||||||
| aliskiren 75 mg vs placebo | 1 | 5 | 821/817 | 8–13 | 0.69 [0.37–1.29] | 0.24 | [0.25–1.90] | 0%(0.52) | 0.008 |
| aliskiren150mg vs placebo | 1 | 7 | 1161/1154 | 8–26 | 0.37[0.16–0.84] | 0.02 | [0.05–2.75] | 38%(0.14) | 0.065 |
| aliskiren300mg vs placebo | 1 | 6 | 984/1001 | 8–26 | 0.60 [0.34–1.06] | 0.08 | [0.21–1.74] | 12%(0.34) | 0.365 |
| aliskiren600mg vs placebo | 1 | 1 | 166/165 | 8 | 0.14 [0.03–0.62] | 0.009 | NA | NA | NA |
| aliskiren vs ARBs | 1 | NR | NR | 4–8 | 0.82 [0.54–1.25] | 0.35 | NR | NR | NR |
| aliskiren vs lorsartan | 1 | NR | NR | 4–8 | 0.76[0.28–2.08] | 0.6 | NR | NR | NR |
| aliskiren vs valsartan | 1 | NR | NR | 8 | 0.89 [0.50–1.58] | 0.69 | NR | NR | NR |
| aliskiren vs irbesartan | 1 | NR | NR | 7–8 | 0.73[0.33–1.61] | 0.43 | NR | NR | NR |
| aliskiren vs ACEIs | 2 | 3 | 1145/952 | 8–36 | 0.76 [0.45–1.28] | 0.3 | [0.00–149.77] | 50%(0.13) | 0.953 |
| aliskiren vs Amlodipine | 1 | 2 | 513/492 | 8–32 | 0.42 [0.08–2.30] | 0.32 | NA | 65% | NA |
| aliskiren vs HCTZ | 1 | 1 | 183/176 | 8 | 1.92 [0.59–6.27] | 0.28 | NA | NA | NA |
| aliskiren vs atenolol | 1 | 1 | 231/231 | 12 | 0.6 [0.22–1.62] | 0.31 | NA | NA | NA |
Notes: Type of metric for comparisons: RR (Risk ratio)
Abbreviations: NA Not Accessible, NR Not Report, SA Systematic review